Ivana Gojo
About
Ivana Gojo is a scholar working on Hematology, Molecular Biology and Oncology.
According to data from OpenAlex, Ivana Gojo has authored 136 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Hematology, 66 papers in Molecular Biology and 46 papers in Oncology. Recurrent topics in Ivana Gojo's work include Acute Myeloid Leukemia Research (88 papers), Histone Deacetylase Inhibitors Research (28 papers) and Acute Lymphoblastic Leukemia research (22 papers). Ivana Gojo is often cited by papers focused on Acute Myeloid Leukemia Research (88 papers), Histone Deacetylase Inhibitors Research (28 papers) and Acute Lymphoblastic Leukemia research (22 papers). Ivana Gojo collaborates with scholars based in United States, Austria and United Kingdom. Ivana Gojo's co-authors include Robert G. Fenton, Judith E. Karp, Luca Vago, Bin Zhang, Bin Zhang, Jacqueline M. Greer, Maria R. Baer, Michael L. Tidwell, Jeffrey E. Lancet and James R. Wright and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.
In The Last Decade
Ivana Gojo
129 papers receiving 4.3k citations
Peers
Ivana Gojo
Gerrit Jan Schuurhuis Netherlands
Nizar J. Bahlis Canada
Walter E. Aulitzky Germany
Juerg Schwaller Switzerland
Virginia M. Klimek United States
Hetty E. Carraway United States
Marc S. Raab Germany
Peter M. Voorhees United States
William Blum United States
Keith W. Pratz United States
Citations per year, relative to Ivana Gojo Ivana Gojo (= 1×)
peers
Gerrit Jan Schuurhuis
Countries citing papers authored by Ivana Gojo
Since
Specialization
Citations
This map shows the geographic impact of Ivana Gojo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivana Gojo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivana Gojo more than expected).
Fields of papers citing papers by Ivana Gojo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ivana Gojo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivana Gojo. The network helps show where Ivana Gojo may publish in the future.
Co-authorship network of co-authors of Ivana Gojo
This figure shows the co-authorship network connecting the top 25 collaborators of Ivana Gojo. A scholar is included among the top collaborators of Ivana Gojo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivana Gojo. Ivana Gojo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mo, Shirley, Alexander J. Ambinder, Amy E. DeZern, et al.. (2025). DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors. Blood. 146(Supplement 1). 1710–1710.
2.
DeZern, Amy E., Marianna Zahurak, Heather J. Symons, et al.. (2025). Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy. 32(3). 310–319.
3.
Webster, Jonathan, Mark J. Levis, Ivana Gojo, et al.. (2025). Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML. PubMed. 2(4). 100133–100133.
4.
Li, Daniel, B. Douglas Smith, Mark J. Levis, et al.. (2024). Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias. Blood. 144(Supplement 1). 5904–5904.
5.
Sanber, Khaled, Hua‐Ling Tsai, Jonathan Webster, et al.. (2023). Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease. Leukemia & lymphoma. 64(4). 846–855.
6.
Karantanos, Theodoros, Hua‐Ling Tsai, Lukasz P. Gondek, et al.. (2022). Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. Leukemia & lymphoma. 63(8). 1942–1948.
7.
Carraway, Hetty E., Yazeed Sawalha, Ivana Gojo, et al.. (2021). Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. Leukemia Research. 110. 106707–106707.
8.
Karantanos, Theodoros, Hua‐Ling Tsai, Lukasz P. Gondek, et al.. (2020). Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN). Blood. 136(Supplement 1). 40–40.
9.
Dalton, W. Brian, Bing Li, Christopher D. Gocke, et al.. (2020). The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. Blood Advances. 4(7). 1192–1196.
10.
Westervelt, Peter, Jörge E. Cortes, Jessica K. Altman, et al.. (2019). Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood. 134(Supplement_1). 834–834.
11.
Zeidan, Amer M., Hanna A. Knaus, Tara M. Robinson, et al.. (2018). A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clinical Cancer Research. 24(15). 3519–3527.
12.
Zeidner, Joshua F., Benjamin G. Vincent, Anastasia Ivanova, et al.. (2017). Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood. 130. 1349–1349.
13.
Webster, Jonathan, Raoul Tibes, Amanda L. Blackford, et al.. (2017). Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leukemia Research. 61. 108–116.
14.
Pratz, Keith W., Michelle A. Rudek, Ivana Gojo, et al.. (2016). A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. Clinical Cancer Research. 23(4). 899–907.
15.
Ravandi, Farhad, Ivana Gojo, Mrinal M. Patnaik, et al.. (2016). A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). Leukemia Research. 48. 92–100.
16.
Gojo, Ivana, Ming Tan, Hong‐Bin Fang, et al.. (2013). Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia. Clinical Cancer Research. 19(7). 1838–1851.
17.
Gojo, Ivana, Alexander E. Perl, Selina M. Luger, et al.. (2013). Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. Investigational New Drugs. 31(5). 1217–1227.
18.
Gore, Steven D., Ivana Gojo, Mikkael A. Sekeres, et al.. (2010). Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia. Journal of Clinical Oncology. 28(6). 1047–1053.
19.
Shiozawa, Ken, Takeo Nakanishi, Ming Tan, et al.. (2009). Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias. Clinical Cancer Research. 15(5). 1698–1707.
20.
Gojo, Ivana, Guido Tricot, R. G. Fenton, et al.. (2000). Autologous stem cell transplantation (ASCT) followed by consolidation chemotherapy for multiple myeloma (MM). Blood. 96.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Gerrit Jan Schuurhuis Breakdown of academic impact, for papers by Nizar J. Bahlis Breakdown of academic impact, for papers by Walter E. Aulitzky Breakdown of academic impact, for papers by Juerg Schwaller Breakdown of academic impact, for papers by Virginia M. Klimek Breakdown of academic impact, for papers by Hetty E. Carraway Breakdown of academic impact, for papers by Marc S. Raab Breakdown of academic impact, for papers by Peter M. Voorhees Breakdown of academic impact, for papers by William Blum Breakdown of academic impact, for papers by Keith W. Pratz